Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders

CONCLUSION: PET/CT resulted in a change in planned management in more than two-thirds of patients with plasma cell disorders in the current selected patient cohort. These results should be validated in a larger prospective trial.